Literature DB >> 21622646

Loss of p19Arf in a Rag1(-/-) B-cell precursor population initiates acute B-lymphoblastic leukemia.

Julia Hauer1, Charles Mullighan, Estelle Morillon, Gary Wang, Julie Bruneau, Nicole Brousse, Marc Lelorc'h, Serge Romana, Amine Boudil, Daniela Tiedau, Sven Kracker, Frederic D Bushmann, Arndt Borkhardt, Alain Fischer, Salima Hacein-Bey-Abina, Marina Cavazzana-Calvo.   

Abstract

In human B-acute lymphoblastic leukemia (B-ALL), RAG1-induced genomic alterations are important for disease progression. However, given that biallelic loss of the RAG1 locus is observed in a subset of cases, RAG1's role in the development of B-ALL remains unclear. We chose a p19Arf(-/-)Rag1(-/-) mouse model to confirm the previously published results concerning the contribution of CDKN2A (p19ARF /INK4a) and RAG1 copy number alterations in precursor B cells to the initiation and/or progression to B-acute lymphoblastic leukemia (B-ALL). In this murine model, we identified a new, Rag1-independent leukemia-initiating mechanism originating from a Sca1(+)CD19(+) precursor cell population and showed that Notch1 expression accelerates the cells' self-renewal capacity in vitro. In human RAG1-deficient BM, a similar CD34(+)CD19(+) population expressed p19ARF. These findings suggest that combined loss of p19Arf and Rag1 results in B-cell precursor leukemia in mice and may contribute to the progression of precursor B-ALL in humans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622646      PMCID: PMC3142899          DOI: 10.1182/blood-2010-09-305383

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

Review 1.  The transcriptional regulation of B cell lineage commitment.

Authors:  Stephen L Nutt; Barbara L Kee
Journal:  Immunity       Date:  2007-06       Impact factor: 31.745

2.  Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.

Authors:  Charles G Mullighan; Richard T Williams; James R Downing; Charles J Sherr
Journal:  Genes Dev       Date:  2008-06-01       Impact factor: 11.361

3.  Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.

Authors:  Richard T Williams; Willem den Besten; Charles J Sherr
Journal:  Genes Dev       Date:  2007-08-30       Impact factor: 11.361

4.  Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.

Authors:  Dengli Hong; Rajeev Gupta; Philip Ancliff; Ann Atzberger; John Brown; Shamit Soneji; Joanne Green; Sue Colman; Wanda Piacibello; Veronica Buckle; Shinobu Tsuzuki; Mel Greaves; Tariq Enver
Journal:  Science       Date:  2008-01-18       Impact factor: 47.728

5.  In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.

Authors:  Christoph le Viseur; Marc Hotfilder; Simon Bomken; Kerrie Wilson; Silja Röttgers; André Schrauder; Annegret Rosemann; Julie Irving; Ronald W Stam; Leonard D Shultz; Jochen Harbott; Heribert Jürgens; Martin Schrappe; Rob Pieters; Josef Vormoor
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

6.  AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.

Authors:  R M Nepal; A Zaheen; W Basit; L Li; S A Berger; A Martin
Journal:  Oncogene       Date:  2008-04-14       Impact factor: 9.867

Review 7.  Regulation of lymphocyte development by Notch signaling.

Authors:  Kenji Tanigaki; Tasuku Honjo
Journal:  Nat Immunol       Date:  2007-05       Impact factor: 25.606

8.  The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene.

Authors:  Pin-Yi Wang; Fay Young; Chun-Yu Chen; Brett M Stevens; Sarah J Neering; Randall M Rossi; Timothy Bushnell; Igor Kuzin; David Heinrich; Andrea Bottaro; Craig T Jordan
Journal:  Blood       Date:  2008-08-28       Impact factor: 22.113

9.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.

Authors:  Charles G Mullighan; Salil Goorha; Ina Radtke; Christopher B Miller; Elaine Coustan-Smith; James D Dalton; Kevin Girtman; Susan Mathew; Jing Ma; Stanley B Pounds; Xiaoping Su; Ching-Hon Pui; Mary V Relling; William E Evans; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2007-04-12       Impact factor: 49.962

10.  DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer.

Authors:  Gary P Wang; Alexandrine Garrigue; Angela Ciuffi; Keshet Ronen; Jeremy Leipzig; Charles Berry; Chantal Lagresle-Peyrou; Fatine Benjelloun; Salima Hacein-Bey-Abina; Alain Fischer; Marina Cavazzana-Calvo; Frederic D Bushman
Journal:  Nucleic Acids Res       Date:  2008-04-14       Impact factor: 16.971

View more
  7 in total

1.  Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice.

Authors:  Tomasz Sewastianik; Meng Jiang; Kumar Sukhdeo; Sanjay S Patel; Kathryn Roberts; Yue Kang; Ahmad Alduaij; Peter S Dennis; Brian Lawney; Ruiyang Liu; Zeyuan Song; Jessie Xiong; Yunyu Zhang; Madeleine E Lemieux; Geraldine S Pinkus; Jeremy N Rich; David M Weinstock; Charles G Mullighan; Norman E Sharpless; Ruben D Carrasco
Journal:  Blood Adv       Date:  2017-11-21

2.  Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.

Authors:  L Olsson; A Castor; M Behrendtz; A Biloglav; E Forestier; K Paulsson; B Johansson
Journal:  Leukemia       Date:  2013-07-04       Impact factor: 11.528

3.  Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.

Authors:  Sheryl M Gough; Yang Jo Chung; Peter D Aplan
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

4.  Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.

Authors:  Blanca Scheijen; Judith M Boer; René Marke; Esther Tijchon; Dorette van Ingen Schenau; Esmé Waanders; Liesbeth van Emst; Laurens T van der Meer; Rob Pieters; Gabriele Escherich; Martin A Horstmann; Edwin Sonneveld; Nicola Venn; Rosemary Sutton; Luciano Dalla-Pozza; Roland P Kuiper; Peter M Hoogerbrugge; Monique L den Boer; Frank N van Leeuwen
Journal:  Haematologica       Date:  2016-12-15       Impact factor: 9.941

5.  Mouse Lymphoblastic Leukemias Induced by Aberrant Prdm14 Expression Demonstrate Widespread Copy Number Alterations Also Found in Human ALL.

Authors:  Stephen J Simko; Horatiu Voicu; Brandi L Carofino; Monica J Justice
Journal:  Cancers (Basel)       Date:  2012-10-18       Impact factor: 6.639

Review 6.  Genetically engineered mouse models of human B-cell precursor leukemias.

Authors:  Julia Hauer; Arndt Borkhardt; Isidro Sánchez-García; César Cobaleda
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Activation-induced cytidine deaminase prevents pro-B cell acute lymphoblastic leukemia by functioning as a negative regulator in Rag1 deficient pro-B cells.

Authors:  Franziska Auer; Deborah Ingenhag; Stefan Pinkert; Sven Kracker; Salima Hacein-Bey-Abina; Marina Cavazzana; Michael Gombert; Alberto Martin-Lorenzo; Min-Hui Lin; Carolina Vicente-Dueñas; Isidro Sánchez-García; Arndt Borkhardt; Julia Hauer
Journal:  Oncotarget       Date:  2017-09-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.